Skip to content

Medical emergency? What to do

Obesity-Related Plasma Hemodilution and PSA Concentration among Men with Prostate Cancer

3-RXPublished February 8, 20083 min read

Key points

  • The important association that increased circulating plasma volumes in obese men may hemodilute PSA and result in lower levels is reported in the November 21, 2007 issue of the Journal of the American Medical Association by Dr.
  • The mean BMI was 28.1, 28.1, and 26.9 for the SEARCH, Duke and Johns Hopkins cohorts, respectively.
  • In summary, obese men had lower PSA values and greater plasma volumes.
  • About UroToday UroToday.com attracts more than 55,000 readers monthly.

The important association that increased circulating plasma volumes in obese men may hemodilute PSA and result in lower levels is reported in the November 21, 2007 issue of the Journal of the American Medical Association by Dr. Banez and associates. This may result in delayed indications for prostate biopsy and detection of prostate cancer (CaP) in obese men, which could contribute to the explanation that obese men present with more aggressive CaP.

The data analyzed came from the VA SEARCH database along with data from Duke University and Johns Hopkins University. The number of patients from these sites was 1,373, 1,974, and 10,287, respectively. Body mass index (BMI) was categorized as normal (<25), overweight (25-29.9), mildly obese (30-34.9), and moderately-severely obese (>35). BMI was examined for association with 3 outcomes variables; serum PSA concentration, plasma volume, and PSA mass. The multivariable model adjusted for a variety of clinical and pathological variables. In particular, to study the relationship of BMI and PSA independent of any association between BMI and CaP severity, cancer-specific variables were also adjusted.

The mean BMI was 28.1, 28.1, and 26.9 for the SEARCH, Duke and Johns Hopkins cohorts, respectively. The total obesity category rates were 30% for SEARCH and Duke and 16% for Johns Hopkins. For all three datasets, higher BMI was more likely in younger patients, more likely to be treated in recent years, and more likely to have a positive surgical margin. In the Duke and Hopkins cohorts men with higher BMI had statistically larger prostates. Higher BMI was significantly associated with greater plasma volume in all groups and (for example) men with a BMI of 35 or greater had 21% to 23% larger plasma volumes relative to normal. After adjusting for multiple variables in the analysis, higher BMI was associated with lower preoperative PSA concentrations in all three cohorts. Patients with a BMI >35 had 11-21% lower PSA concentrations relative to normal weight patients.

The association between BMI and PSA mass reflects the total amount of PSA protein in circulation. Only in the Johns Hopkins cohort did PSA mass significantly increase with increasing BMI. The authors determined that this was driven by lower PSA mass in normal weight men and after exclusion of normal weight men there was no significant association.

In summary, obese men had lower PSA values and greater plasma volumes. This data suggests that hemodilution from greater plasma volume may lower PSA values in obese men. Prospective validation is needed but the potential implication is that obese patients may have a delay in CaP diagnosis due to the lower PSA concentrations.

Reference:
JAMA. 298(19):2275-80, November 21, 2007
Bañez LL, Hamilton RJ, Partin AW, Vollmer RT, Sun L, Rodriguez C, Wang Y, Terris MK, Aronson WJ, Jr . Presti JC, KaneCJ, Amling CL, Moul JW, Freedland SJ

Reported by Christopher P. Evans, MD, a Contributing Editor with UroToday.

About UroToday
UroToday.com attracts more than 55,000 readers monthly. The website covers over 22 urology disease categories and provides the most in depth Urological conference reports available online. UroToday.com is the world leader in delivering a quality, global online publication providing accurate and timely education that is clinically relevant in the practice of Urology. All scientific content is developed by urologists committed to translating research into clinically relevant science, including all genitourinary cancers, pediatric and geriatric urological dysfunctions for urologists, medical oncologists, advanced nurse practitioners and other medical professionals.

Source: UroToday

The content on this site is for information only and is not a substitute for professional medical advice, diagnosis or treatment. Drug information pages are an archive and may be out of date: always follow your prescriber, your pharmacist and the current product label. In an emergency, call 911.

Keep reading

When to get help

Reading is for later. These need care now.

Call 911 or go to an emergency department if you or someone with you has any of these:

  • Chest pain or pressureEspecially with breathlessness, sweating or pain in the arm, jaw or back. It can be a heart attack.
  • Face drooping, arm weakness, slurred speechSigns of a stroke. Note the time they started: treatment works best within hours.
  • Severe trouble breathingIncluding a severe allergic reaction with swelling of the lips, tongue or throat.
  • Thoughts of suicideCall or text 988 (Suicide & Crisis Lifeline, US) any time, day or night.

Outside the US, call your local emergency number.

See a doctor within days

  1. 01A new lump, or a sore that does not healMost lumps are harmless, but anything that grows or lasts more than a few weeks should be checked.
  2. 02Unexplained weight loss or lasting fatigueLosing weight without trying, or tiredness that does not lift, can have many causes worth finding.
  3. 03A new medicine and new symptomsSide effects and interactions are common. Ask your pharmacist or prescriber before you stop anything.

General guidance only. If you are unsure how urgent a symptom is, call your doctor or a nurse advice line.